These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 28591789

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
    Pettit NN, DePestel DD, Fohl AL, Eyler R, Carver PL.
    Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
    Chilton CH, Freeman J, Crowther GS, Todhunter SL, Wilcox MH.
    J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.
    Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME.
    Int J Antimicrob Agents; 2012 Jul; 40(1):1-8. PubMed ID: 22398198
    [Abstract] [Full Text] [Related]

  • 27. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ.
    Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030
    [Abstract] [Full Text] [Related]

  • 28. Clostridium difficile-associated disease treatment response depends on definition of cure.
    Lawrence SJ, Dubberke ER, Johnson S, Gerding DN.
    Clin Infect Dis; 2007 Dec 15; 45(12):1648; author reply 1649-51. PubMed ID: 18190331
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
    Hung YP, Lin HJ, Wu CJ, Chen PL, Lee JC, Liu HC, Wu YH, Yeh FH, Tsai PJ, Ko WC.
    Anaerobe; 2014 Dec 15; 30():24-6. PubMed ID: 25102472
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Tart SB.
    J Pharm Pract; 2013 Oct 15; 26(5):488-90. PubMed ID: 23940121
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Repeated Clostridium difficile infection after living donor liver transplantation.
    Abe K, Shiba H, Furukawa K, Sakamoto T, Ishida Y, Yanaga K.
    Clin J Gastroenterol; 2018 Aug 15; 11(4):309-311. PubMed ID: 29497978
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.
    Wu MA, Leidi F, Gruppo di Autoformazione Metodologica (GrAM).
    Intern Emerg Med; 2017 Sep 15; 12(6):871-872. PubMed ID: 28681270
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.